923009-79-4

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 5437-45-6 Benzyl bromoacetate 

Downstream Products

• 1042441-53-1 1'-tert-butyl 3-ethyl 3-[2-(benzyloxy)-2-oxoethyl]-1,4'-bipiperidine-1',3-dicarboxylate 
• 1380610-25-2 1'-tert-butyl (3S)-3-ethyl 3-[2-(benzyloxy)-2-oxoethyl]-1,4'-bipiperidine-1',3-dicarboxylate 
• 1380610-22-9 1'-tert-Butyl (3R)-3-ethyl 3-[2-(benzyloxy)-2-oxoethyl]-1,4'-bipiperidine-1',3-dicarboxylate 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.